Occupational Activity – Page 32

Revolutionizing Medicine: The Evolution and Future of Cell and Gene Therapy Manufacturing

1 year ago talkbio0Tagged Automation, biomanufacturing, CAR-T, Cell Therapy, gene therapy, Manufacture, Precision Medicine, regulatory, scale-up, Stem Cell Therapy, Viral Vector

Cell therapy manufacturing, gene therapy manufacturing, biomanufacturing, advanced therapies, CAR-T cell therapy, stem cell therapy, viral vectors, bioreactors, automation, scale-up, regulatory compliance, personalized medicine.

Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management

1 year ago talkbio0Tagged Administration occupational activities, Biological Factors, Collaboration, Diabetes, Eli, Eli Lilly, GLUCOSE CONTROL, Innovent, Metabolic Diseases, next-generation therapy, Obesity, Phase 3 trials

Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.

Attovia Secures $105M for Multiple Trials of Innovative Industrial and Institutional Biologics

1 year ago talkbio0Tagged Attovia, Biological Factors, Clinical Trials, crossover investors, Industry, institutional

Attovia, biologics, industrial and institutional (I&I), crossover investors, funding, clinical trials

ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Biotechnology, Cancer Therapeutic Procedure, Clinical Trials, Health care facility, Mucosa-Associated Lymphoid Tissue Lymphoma, Sales - occupational activity, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics, Zynlonta, marginal zone lymphoma, share sale, funding, cancer treatment, antibody-drug conjugate, clinical trials, biotechnology, healthcare.

Pfizer Appoints Citi Analyst Andrew Baum as New Strategy Chief

1 year ago talkbio0Tagged Andrew Baum, Chief, Citi, Drug Industry, Leadership Change, Pfizer, Strategic Planning, Strategy

Pfizer, Andrew Baum, Citi analyst, strategy chief, pharmaceutical industry, leadership change, strategic planning.

Reunion Neuroscience Secures $103 Million to Advance Psychedelic Therapies for Patients

1 year ago talkbio0Tagged Clinical Trials, Industry, mental health, mental health innovation, Neuroscience discipline, patient care, psychedelic therapies, Reunion Island

Reunion Neuroscience, psychedelic therapies, mental health, fundraising, clinical trials, mental health treatments, alternative therapies, mental health innovation, patient care, biotech industry.